Business Description
Ceryvyn Therapeutics Ltd
ISIN : AU0000478117
Total Employee Number:
10Description
Ceryvyn Therapeutics Ltd is a clinical-stage biopharmaceutical company developing therapies by translating advances in human biology into transformative medicines for patients with serious diseases. The Company seeks to identify biological mechanisms that drive disease and develop targeted therapies capable of addressing unmet medical need. Its current focus is lymphangioleiomyomatosis (LAM) - a rare, chronic and progressive systemic disease that predominantly affects women and involves the lungs, where it leads to progressive loss of lung function. The Company's main development program, CYV-101, is a first-in-class fusion protein designed to selectively bind and neutralise VEGF-C and VEGF-D, key signalling proteins involved in pathological lymphangiogenesis.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.3 | |||||
Equity-to-Asset | -3.54 | |||||
Debt-to-Equity | -0.8 | |||||
Debt-to-EBITDA | -1.28 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -29.69 | |||||
Beneish M-Score | -6.13 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 27.2 | |||||
3-Year EPS without NRI Growth Rate | 14 | |||||
3-Year FCF Growth Rate | 11.7 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 844.36 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 19.83 | |||||
9-Day RSI | 7.34 | |||||
14-Day RSI | 3.83 | |||||
3-1 Month Momentum % | -97.83 | |||||
6-1 Month Momentum % | -97.83 | |||||
12-1 Month Momentum % | -97.83 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.22 | |||||
Quick Ratio | 0.22 | |||||
Cash Ratio | 0.19 | |||||
Days Sales Outstanding | 17857.63 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -44.8 | |||||
Shareholder Yield % | -1187.88 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -594040 | |||||
Net Margin % | -639297.5 | |||||
EBITDA Margin % | -485487.5 | |||||
FCF Margin % | -617045 | |||||
OCF Margin % | -616992.5 | |||||
ROA % | -127.49 | |||||
ROIC % | -131.18 | |||||
3-Year ROIIC % | -25.5 | |||||
ROC (Joel Greenblatt) % | -116601 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio without NRI | 0.57 | |||||
EV-to-EBIT | -0.27 | |||||
EV-to-EBITDA | -0.27 | |||||
EV-to-Revenue | 1329.13 | |||||
EV-to-Forward-Revenue | 156.71 | |||||
EV-to-FCF | -0.22 | |||||
Earnings Yield (Greenblatt) % | -370.37 | |||||
FCF Yield % | -1503.52 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ceryvyn Therapeutics Ltd Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | 0.04 | ||
| EPS (TTM) (A$) | -0.209 | ||
| Beta | 2.6279 | ||
| 3-Year Sharpe Ratio | -0.09 | ||
| 3-Year Sortino Ratio | -0.11 | ||
| Volatility % | 97.5 | ||
| 14-Day RSI | 3.83 | ||
| 14-Day ATR (A$) | 0.006885 | ||
| 20-Day SMA (A$) | 0.014 | ||
| 12-1 Month Momentum % | -97.83 | ||
| 52-Week Range (A$) | 0.012 - 0.6 | ||
| Shares Outstanding (Mil) | 1,367.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ceryvyn Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ceryvyn Therapeutics Ltd Stock Events
| Event | Date | Price (A$) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2026-09-15 | In 65 days | ||
| Fourth quarter earnings results for 2026 | 2026-08-28 | In 47 days | ||
| Second quarter earnings results for 2026 | 2026-03-02 | 0.60 (+0.00%) | ||
| Annual report for 2025 | 2025-09-15 | 0.60 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2025-08-29 | 0.60 (+0.00%) | ||
| Oppenheimer’s 35th Annual Healthcare Life Sciences Conference | 2025-02-11 10:00 | 1.09 (-1.80%) | ||
| Opthea Investor Day | 2025-02-05 16:30 | 1.08 (+3.85%) | ||
| Opthea Investor Day | 2025-02-03 16:30 | 1.14 (+7.04%) | ||
| 43rd Annual J.P. Morgan Healthcare Conference | 2025-01-15 17:15 | 0.80 (+5.96%) | ||
| Guidance call for 2024 | 2024-12-05 13:45 | 0.72 (-3.38%) |
Show
Entries
Ceryvyn Therapeutics Ltd Frequently Asked Questions
What is Ceryvyn Therapeutics Ltd(ASX:CYV)'s stock price today?
The current price of ASX:CYV is A$0.01. The 52 week high of ASX:CYV is A$0.60 and 52 week low is A$0.01.
When is next earnings date of Ceryvyn Therapeutics Ltd(ASX:CYV)?
The next earnings date of Ceryvyn Therapeutics Ltd(ASX:CYV) is 2026-08-28 Est..
Does Ceryvyn Therapeutics Ltd(ASX:CYV) pay dividends? If so, how much?
Ceryvyn Therapeutics Ltd(ASX:CYV) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Ceryvyn Therapeutics Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers